Cargando…

Antiangiogenic Therapy in Clear Cell Renal Carcinoma (CCRC): Pharmacological Basis and Clinical Results

SIMPLE SUMMARY: In the last 15 years, a deep improvement in the knowledge regarding the biological mechanisms responsible for neoplastic cell development and progression has led to a dramatic change in the treatment landscape of metastatic clear cell renal carcinoma. Nowadays, it is known that neo-a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Comandone, Alessandro, Vana, Federica, Comandone, Tiziana, Tucci, Marcello
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8656563/ https://www.ncbi.nlm.nih.gov/pubmed/34885006 http://dx.doi.org/10.3390/cancers13235896

Ejemplares similares

A Pharmacological Analysis of the Activity and Failure of the Medical Treatment of High-Grade Osteosarcoma
por: Comandone, Alessandro, et al.
Publicado: (2021)

CCRC08 - View from Sites
por: Harry Renshall, et al.
Publicado: (2008)

The WLCG common computing readiness challenge: CCRC`08
por: Mendez Lorenzo, Patricia, et al.
Publicado: (2008)

CCRC08 - View from WLCG Service
por: Jamie Shiers
Publicado: (2008)

POTENTIAL BENEFITS FROM LIVING IN A CCRC
por: Wyatt-Brown, Anne
Publicado: (2019)

The (WLCG) Common Computing Readiness Challenge (CCRC'08)
por: Shiers, Jamie
Publicado: (2008)

CCRC'08 Post-mortem workshop in June (12-13)
por: CERN. Geneva
Publicado: (2008)

Molecular Mechanisms of Resistance to Immunotherapy and Antiangiogenic Treatments in Clear Cell Renal Cell Carcinoma
por: Ballesteros, Pablo Álvarez, et al.
Publicado: (2021)

Electronic Assisted Living Technology in CCRC, Assisted Living, and In-Home Care
por: Hall, John, et al.
Publicado: (2020)

Mexican Colorectal Cancer Research Consortium (MEX-CCRC): Etiology, Diagnosis/Prognosis, and Innovative Therapies
por: Andrade-Meza, Antonio, et al.
Publicado: (2023)

Benign Mesothelial Proliferations of the Tunica Vaginalis Testis
por: Manini, Claudia, et al.
Publicado: (2023)

Ultrasound Molecular Imaging of VEGFR-2 in Clear-Cell Renal Cell Carcinoma Tracks Disease Response to Antiangiogenic and Notch-Inhibition Therapy
por: Rojas, Juan D., et al.
Publicado: (2018)

Follow-up on Action Items from April CCRC'08 F2F
por: CERN. Geneva
Publicado: (2008)

Systems pharmacology approaches for optimization of antiangiogenic therapies: challenges and opportunities
por: Sharan, Satish, et al.
Publicado: (2015)

Application basis of combining antiangiogenic therapy with radiotherapy and immunotherapy in cancer treatment
por: Yuan, Meng, et al.
Publicado: (2022)

The pharmacological bases of the antiangiogenic activity of paclitaxel
por: Bocci, Guido, et al.
Publicado: (2013)

Oncological patient management on the territory: the results of a survey in the north-west of Italy
por: Baratta, Francesca, et al.
Publicado: (2022)

Biochemical Properties and Potential Applications of Recombinant Leucine Aminopeptidase from Bacillus kaustophilus CCRC 11223
por: Shen, Yanfei, et al.
Publicado: (2011)

Antiangiogenic therapy for advanced renal cell carcinoma: Management of treatment-related toxicities
por: Cohen, Roger B., et al.
Publicado: (2012)

The need for kidney biopsy in the management of side effects of target and immunotherapy
por: Fenoglio, Roberta, et al.
Publicado: (2023)

Antiangiogenic therapy
por: Avitabile, T
Publicado: (2010)

Resistance to Antiangiogenic Therapies by Metabolic Symbiosis in Renal Cell Carcinoma PDX Models and Patients
por: Jiménez-Valerio, Gabriela, et al.
Publicado: (2016)

Enhancing Antitumor Immunity with Antiangiogenic Therapy: A Clinical Model in Renal Cell Carcinoma?
por: Gao, Xin, et al.
Publicado: (2019)

Combining antiangiogenic therapy and radiation in nasopharyngeal carcinoma
por: Chen, Zhuo, et al.
Publicado: (2015)

Draft Genome Sequence of Streptomyces albulus Strain CCRC 11814, an ε-Poly-l-Lysine-Producing Actinomycete
por: Dodd, Amanda, et al.
Publicado: (2013)

Novel concepts of antiangiogenic therapies in metastatic renal cell cancer
por: Pichler, Renate, et al.
Publicado: (2017)

The inefficacy of antiangiogenic therapies
por: Ribatti, Domenico
Publicado: (2010)

Antiangiogenic Therapy for Glioma
por: Cea, Valentina, et al.
Publicado: (2012)

Antiangiogenic Cancer Therapy
por: Maxwell, P H, et al.
Publicado: (2009)

Navigating and adapting care integrating immunotherapy, antiangiogenic therapy, and combinations in patients with advanced renal cell carcinoma
por: Rini, Brian I, et al.
Publicado: (2023)

Solitary pancreatic head metastasis from tibial adamantinoma: a rare indication to pancreaticoduodenectomy
por: Silvestri, S, et al.
Publicado: (2018)

The Role of Epigenetics in the Progression of Clear Cell Renal Cell Carcinoma and the Basis for Future Epigenetic Treatments
por: Angulo, Javier C., et al.
Publicado: (2021)

Inhibitory effect on expression of angiogenic factors by antiangiogenic agents in renal cell carcinoma
por: Sasamura, H, et al.
Publicado: (2002)

Antiangiogenic therapy for breast cancer
por: Nielsen, Dorte Lisbet, et al.
Publicado: (2010)

Antiangiogenic therapies in ovarian cancer
por: Reinthaller, Alexander
Publicado: (2016)

Antiangiogenic therapy in breast cancer
por: Gampenrieder, Simon Peter, et al.
Publicado: (2017)

Antiangiogenic Therapy for Diabetic Nephropathy
por: Tanabe, Katsuyuki, et al.
Publicado: (2017)

Quantitative Insight in Utilizing Circulating Angiogenic Factors as Biomarkers for Antiangiogenic Therapy: Systems Pharmacology Approach
por: Sharan, S, et al.
Publicado: (2014)

Synergies of Antiangiogenic Therapy and Immune Checkpoint Blockade in Renal Cell Carcinoma: From Theoretical Background to Clinical Reality
por: Zhou, Xiaohan, et al.
Publicado: (2020)

Integrated transcriptional‐phenotypic analysis captures systemic immunomodulation following antiangiogenic therapy in renal cell carcinoma patients
por: Rinchai, Darawan, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_4qf9uqgh68sem5ncbtfrq9s10v